Westfield Capital Management
KERX

Westfield Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Westfield Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-27,700
Closed -$207K – 381
2013
Q2 		$207K Buy
+27,700
New +$216K ﹤0.01% 349

Other funds holding KERX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Westfield Capital Management's KERX Position: Q3 2013 in Review

Westfield Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2013, closing a stake of 27,700 shares — an estimated $207K sold.

Westfield Capital Management first reported a position in KERX in Q2 2013 and held it in 1 quarter. The position peaked at $207K in Q2 2013. 110 funds tracked by Wall St. Rank hold KERX as of Q3 2013.

  • Westfield Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2013 after selling out during the quarter.
  • Westfield Capital Management sold 27,700 Keryx Biopharmaceuticals Inc shares in Q3 2013, an estimated $207K.
  • Westfield Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 1 quarter.
  • Westfield Capital Management's Keryx Biopharmaceuticals Inc position peaked at $207K in Q2 2013.
  • 110 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2013.

Based on Westfield Capital Management's 13F filing for Q3 2013, filed 12 Nov 2013.